Acceptable test to confirm diagnosis for individuals with clinical phenotype of Marfan syndrome.
Polymerase Chain Reaction/Sequencing
Lavender (EDTA), pink (K2EDTA) or yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Background information for Marfan Syndrome, FBN1 Sequencing:
Characteristics: Aortic root dilatation/dissection, ectopia lentis, positive wrist and/or thumb sign, pectus carinatum or excavatum, hindfoot deformity, pneumothorax, dural ectasia, acetabular protrusion, scoliosis or thoracolumbar kyphosis, reduced upper/lower segment ratio and increased arm/height ratio in persons without severe scoliosis, reduced elbow extension, skin striae, myopia, mitral valve prolapse, and specific facial features.
Prevalence: 1 in 5,000 - 1 in 10,000.
Inheritance: Autosomal dominant.
Penetrance: 100 percent, age-dependent.
Cause: Pathogenic FBN1 gene mutations.
Clinical Sensitivity: 70-93 percent.
Methodology: Bidirectional sequencing of the entire FBN1 coding region and intron-exon boundaries.
Analytical Sensitivity and Specificity: Greater than 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, deep intronic mutations and large deletions/duplications will not be detected. Mutations in genes other than FBN1 are not evaluated.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2005590||Marfan Syndrome (FBN1) Seq Specimen|
|2005591||Marfan Syndrome (FBN1) Seq Interp||77114-7|
- FBN1 genetic
- FBN1 Sequencing
- FBN1 sequencing and deletion/duplication assay